Immunotherapy, particularly PD-1/PD-L1 and CTLA-4 checkpoint inhibitors, has transformed gynecological cancer treatment, showing efficacy in uterine, ovarian, and endometrial cancers [46, 47]. This evidence concerns the gene CTLA4 and endometrial cancer.